The world was shut down for a virus. One that many claimed would kill millions in the US. Everyone is on the edge of their seat waiting for the promise of a return to life as normal. And for many people this would mean a vaccine.
But what happens when the hope of our salvation is one that doesn’t even test for safety or efficacy of these vaccines?
That’s right. None of the vaccine trials have been set up to test for the only purpose this vaccine program was created for. Nor do they test for the one group at most risk: The Elderly. Meaning, the vaccine trials could fail to elicit warning signs in their limited timeframe, and the downstream health effects on the vaccinated would be unknown.
Dr. Peter Doshi’s article in the British Medical Journal on October 21st expanded on these concerns, and he is far from alone.
“Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, said, ‘Ideally, you want an antiviral vaccine to do two things . . . first, reduce the likelihood you will get severely ill and go to the hospital, and two, prevent infection and therefore interrupt disease transmission.’
Yet the current phase III trials are not actually set up to prove either…”
It comes down to a matter of time and money.
Most people that develop symptoms with COVID-19 (and there are plenty that do not) have a mild symptomatic response. To adequately test for a reduction in severe outcomes—the only ones we care about—it would be necessary to increase the size of the trial by many factors, or to increase the length of the trial. Neither option is politically tenable, nor does it offer a solution to the media-fueled fear rampage that has been unleashed.
Dr. Doshi writes, “In the trials, final efficacy analyses are planned after just 150 to 160 ‘events,’—that is, a positive indication of symptomatic covid-19, regardless of severity of the illness.”
In other words, only 150 infections detected in a trial group of 30,000 is what is needed to determine if the vaccine is “effective”. A minuscule number that does not even include the elderly.
This is a very low bar to achieve for something some may want to mandate, and will likely be administered to hundreds of millions.
Dr. Doshi also writes, “Hospital admissions and deaths from covid-19 are simply too uncommon in the population being studied for an effective vaccine to demonstrate statistically significant differences in a trial of 30 000 people. The same is true of its ability to save lives or prevent transmission: the trials are not designed to find out.”
Even the chief medical officer at Moderna admits the trial lacks adequate statistical power to assess if the vaccine is effective at reducing death and severe illness.
The article goes on to note: “History shows many examples of serious adverse events from vaccines brought to market in periods of enormous pressure and expectation. There were contaminated polio vaccines in 1955, cases of Guillain-Barré syndrome in recipients of flu vaccines in 1976, and narcolepsy linked to one brand of influenza vaccine in 2009.”
These trials have every indication that they are being rushed beyond the point of reason, to produce a product that has an unknown outcome, and unknown health impact years down the line.
And why should we wait for a vaccine to return to life as normal when safe and effective treatments already exist for the few people that need help with a COVID-19 infection.
Visit HealthyImmunityNow.org to learn more and Be Free!